Biocon shares gain 4% despite net profit declining 57%; check all Q4 numbers

Biocon shares on Friday, May 8, climbed as much as 3.6% to touch an intraday high of ₹396.40 apiece despite the pharmaceutical major reporting a decline in its net profit for the quarter ended March 31, 2026.

The company has posted a 57% fall in its consolidated net profit at ₹199 crore in Q4 FY26, hit by an exceptional item outgo of ₹80.4 crore on various heads, including the impact of the new labour code.

The company had posted a consolidated net profit of ₹459 crore in the corresponding period of the previous fiscal, Biocon said.

Its revenue from operations in the reporting quarter was at ₹4,516.6 crore as against ₹4,417 crore in the year-ago period.

Total expenses in the fourth quarter were higher at ₹4,241.2 crore as compared to ₹3,987.5 crore in the same period a year ago.

Along with its earnings, Biocon's board of directors has also recommended a final dividend of 50 paise per equity share of face value of ₹5 each for the financial year ended March 31, 2026, subject to shareholders' approval at the ensuing annual general meeting.

For FY26, Biocon’s consolidated net profit was at ₹368.8 crore, down from ₹1,429.4 crore in FY25. The revenue from operations in FY26 stood at ₹16,927 crore as against ₹15,261.7 crore in FY25.

Management commentary

“Biocon closed FY26 on a strong note despite a complex geopolitical environment. We delivered margin expansion along with 13 per cent YoY growth in operating revenue, excluding the one-time impact of generic lenalidomide sales last year,” Biocon Ltd Executive Chairperson Kiran Mazumdar-Shaw said.

She further said, “This performance reflects the resilience of our business and disciplined execution through a pivotal year of integration.”

Biocon has created a unified biopharma entity by integrating the biosimilars business with generics formulations and the APIs business, Mazumdar-Shaw said, adding the combined business has a stronger balance sheet, improved leverage metrics and a more global commercial footprint.

The company said Shreehas Tambe has taken charge as CEO & Managing Director of Biocon Ltd on April 1, 2026, with Kedar Upadhye appointed as chief financial officer.

Biocon share price

At 12:20 PM, Biocon shares were trading at ₹390.55 apiece on the National Stock Exchange, rising 3.35%.

In the last five days, shares of the firm gained 7%, while for a month's time, they have climbed 11%. The company has a market capitalisation of ₹62,818.28 crore.

Shares of the company had touched their one-year high of ₹424.95 apiece on November 18, 2025, while their 52-week low of ₹317.90 was hit on May 12, 2025.